Because depletion of KDM3C causes minor defects in normal hematopoiesis [48], disrupting its activity with small-molecule inhibitors may be advantageous in AML-type patients [58, 60], outweighing the minimal adverse effects caused upon inhibition. This evidence concerns the gene JMJD1C and acute myeloid leukemia.